Forgot your password? Enter the email address you used to create your account to initiate a password reset.
H. Henry Dong, PhD, professor of pediatrics in the Department of Pediatrics at the University of Pittsburgh School of Medicine and the Division of Pediatric Endocrinology, Diabetes, and Metabolism at UPMC Children’s Hospital of Pittsburgh, studies the molecular basis that links insulin resistance to diabetic dyslipidemia and nonalcoholic fatty liver disease in subjects with morbid obesity and type 2 diabetes.
Insulin resistance is the significantly diminished state of responsiveness of the body to normal plasma insulin concentrations. To overcome insulin resistance in peripheral tissues, pancreatic beta cells are recruited to produce more insulin via a compensatory mechanism. Over time, this compensatory pathway can lead to beta-cell failure and overt type 2 diabetes in human subjects who exhibit morbid obesity.
Dr. Dong’s lab focuses on the characterization of genetic factors in glucose and lipid metabolism to understand how insulin resistance perturbs carbohydrate metabolism, contributing to the development of diabetic dyslipidemia and nonalcoholic fatty liver disease in obesity and type 2 diabetes. These studies have gathered insight into the molecular events that link insulin resistance to metabolic abnormalities, providing a knowledge base for the development of small molecule drugs for better clinical management of diabetic dyslipidemia and nonalcoholic fatty liver disease in obesity and type 2 diabetes.
“We know that individuals with obesity and type 2 diabetes have two things in common: insulin resistance and low-grade inflammation. The inflammation is categorized by consistent production of the pro-inflammatory cytokine IL-1β. The molecular mechanisms that couple insulin resistance with this low-grade inflammation seen in obesity and type 2 diabetes is not well understood,” says Dr. Dong.
However, while these mechanisms that link the two states together have yet to be fully explained, Dr. Dong’s team in prior research has identified a key downstream regulator of insulin signaling — the forkhead box 01 (Fox01) transcription factor.
“This is a unique protein. It mediates the inhibitory action of insulin. Usually, insulin positively impacts the body by lowering blood glucose levels, promoting cell growth, and fostering cell differentiation. However, insulin also has an inhibitory action, and the Fox01 protein is the transcription factor that mediates the inhibitory action of insulin,” says Dr. Dong.
In 2008, Dr. Dong and colleagues published a paper in the Journal of Clinical Investigation related to the role of Fox01 in hepatic insulin signaling. Their animal model research linked an increase in Fox01 activity with increases in microsomal triglyceride transfer protein (MTP) expression, increased very-low-density lipoprotein (VLDL) production, and consequently higher levels of plasma triglycerides.
“We found that Fox01 plays a key role in lipid metabolism in the liver and that Fox01 is responsible for mediated insulin function on its MTP target,” says Dr. Dong.
In 2009, in the journal Diabetes, Dr. Dong and colleagues published findings that showed the Fox01 protein is responsible for regulating the expression of IL-1β and that it plays an important role in the linking of insulin resistance and inflammation in type 2 diabetes and obesity.
“The immune or inflammatory response appears to be primarily carried out or propagated by Fox01 dysregulated macrophages that produce enhanced levels of IL-1β,” says Dr. Dong.
It is on the basis of these and other prior findings that Dr. Dong pursued and obtained a new grant to continue his Fox01 studies.
In 2019, Dr. Dong was awarded a new National Institutes of Health (NIH) R01 grant to continue his studies elucidating the molecular mech-anisms by which the Fox01 transcription factor mediates insulin resistance and inflammation and the regulation of abnormal macrophage activity. This research will build upon the considerable knowledge base he has worked to uncover previously on the Fox01 transcription factor and its functions. If successful in proving their hypothesis, Dr. Dong’s research could lead to an understanding of Fox01 as a target for drug therapies to mitigate insulin resistance and low-grade inflammation.
Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. Fox01 Mediates Insulin-Dependent Regulation of Hepatic VLDL Production in Mice. J Clin Invest. 2008; 118(6): 2347-2364.
Su D, Coudriet GM, Kim DH, Yu Y, Perdomo G, Qu S, Slusher S, Tse HM, Piganelli J, Giannoukakis N, Zhang J, Dong HH. Fox01 Links Insulin Resistance to Proinflammatory Cytokine IL-1β Production in Macrophages. Diabetes. 2009; 58: 2624-2633.